Crimean-Congo hemorrhagic fever: A pediatric case responding to plasmapheresis treatment

Transfus Apher Sci. 2021 Dec;60(6):103215. doi: 10.1016/j.transci.2021.103215. Epub 2021 Jul 29.

Abstract

Crimean-Congo hemorrhagic fever (CCHF) is a life-threatening tick-borne viral infection. The most important step in the treatment of CCHF is supportive therapy. Ribavirin is the recommended antiviral agent for infected patients. We present a case of a child who presented to our pediatric intensive care unit due to CCHF and was treated with plasmapheresis and ribavirin. A previously healthy seven-month-old male infant presented to the emergency room with a fever of 39.5 °C, nosebleed, cough, vomiting, and weakness. We decided to apply plasmapheresis treatment due to multiple organ failure associated with thrombocytopenia, acute liver failure, and a family history of death from the disease. Plasmapheresis was performed in three sessions. By the sixth day of his admission to the intensive care unit, the patient's clinical condition had improved and his laboratory values had returned to normal, so he was transferred to the infectious diseases service in stable condition.

Keywords: Children; Crimean-Congo hemorrhagic fever; Pediatric intensive care; Ribavirin; Therapeutic plasma exchange.

Publication types

  • Case Reports

MeSH terms

  • Hemorrhagic Fever, Crimean / therapy*
  • Humans
  • Infant
  • Male
  • Plasmapheresis / methods*
  • Ribavirin / therapeutic use

Substances

  • Ribavirin